Heat-Shock Protein 90-Targeted Nano Anticancer Therapy

Journal of Pharmaceutical Sciences

Volumn 105, Issue 4, 2016, Pages 1454-1466

  Rochani, Ankit K ^a   Ravindran Girija, Aswathy ^a   Borah, Ankita ^a   Maekawa, Toru ^a   Sakthi Kumar, D ^a  

^a TOYO UNIVERSITY   (Japan)

Author keywords

biomaterials; cancer; cancer chemotherapy; drug resistance; nanoparticles; nanotechnology

Indexed keywords

ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; CHAPERONE; DAUNORUBICIN; DOXORUBICIN; DRUG VEHICLE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; LIPOSOME; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NANOPARTICLE; NANOSHELL; NANOVECTOR; PACLITAXEL; POLYMER; RETASPIMYCIN; TANESPIMYCIN; UNCLASSIFIED DRUG; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; BIODEGRADABILITY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; HUMAN; LIPOSOMAL DELIVERY; MICELLE; MULTIDRUG RESISTANCE; NANOTECHNOLOGY; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG RESISTANCE; METABOLISM; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84964491370     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2015.10.007     Document Type: Article

References (183)

1. History of cancer. Available at: http://www.cancer.org/cancer/cancerbasics/thehistoryofcancer/the-history-of-cancer-what-is-cancer. Accessed September 14, 2015.
2. Statistics for different kinds of cancer. Available at: http://www.cdc.gov/cancer/dcpc/data/types.htm. Accessed September 14, 2015.
3. Cancer Fact Sheet. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed September 14, 2015.
4. A. Urruticoechea, R. Alemany, J. Balart, A. Villanueva, F. Viñals, and G. Capellá Recent advances in cancer therapy: an overview Curr Pharm Des 16 2010 3 10
5. P. Christakis The birth of chemotherapy at Yale: bicentennial lecture series: surgery grand round Yale J Biol Med 84 2011 169 172
6. D.R. Miller A tribute to Sidney Farber - The father of modern chemotherapy Br J Haematol 134 1 2006 20 26
7. T. Connors Anticancer drug development: the way forward Oncologist 1 1996 180 181
8. R. Kumar, K. Chaudhary, S. Gupta, and et al. CancerDR: cancer drug resistance database Sci Rep 3 2013 1445
9. Cancer treatment. Available at: http://www.cancer.gov/research/areas/treatment. Accessed September 14, 2015.
10. R.A. Burrell, N. McGranahan, J. Bartek, and C. Swanton The causes and consequences of genetic heterogeneity in cancer evolution Nature 501 2013 338 345
11. M.A. Arslan, O. Kutuk, and H. Basaga Protein kinases as drug targets in cancer Curr Cancer Drug Targets 6 2006 623 634
12. N.H. Nam, and K. Parang Current targets for anticancer drug discovery Curr Drug Targets 4 2003 159 179
13. L. Neckers, and J.B. Trepel Stressing the development of small molecules targeting HSP90 Clin Cancer Res 20 2014 275 277
14. A.S. Don, and X.F. Zheng Recent clinical trials of mTOR-targeted cancer therapies Rev Recent Clin Trials 6 2011 24 35
15. J. Acquaviva, S. He, J. Sang, and et al. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis Mol Cancer Res 12 5 2014 703 713
16. Q. Liu, C. Thoreen, J. Wang, D. Sabatini, and N.S. Gray mTOR mediated anti-cancer drug discovery Drug Discov Today Ther Strateg 6 2009 47 55
17. L. Seguin, S. Kato, A. Franovic, and et al. An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition Nat Cell Biol 16 5 2014 457 468
18. S.M. Weis, and D.A. Cheresh A wake-up call for hibernating tumour cells Nat Cell Biol 15 2013 721 723
19. Stem cells increase in cancer patients possibly from drug resistance. Available at: http://guardianlv.com/2014/04/stem-cells-increase-in-cancer-patients-possibly-from-drug-resistance/#ybSLPx8hD5bCzjB6.99. Accessed September 14, 2015.
20. R. De Souza, P. Zahedi, R.M. Badame, C. Allen, and M. Piquette-Miller Chemotherapy dosing schedule influences drug resistance development in ovarian cancer Mol Cancer Ther 10 2011 1289 1299
21. A.J. Davis, W. Chapman, D.W. Hedley, A.M. Oza, and I.F. Tannock Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study Cytometry A 51 2003 1 6
22. L. Wu, and I.F. Tannock Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil Cancer Res 63 2003 2134 2138
23. B. Haley, and E. Frenkel Nanoparticles for drug delivery in cancer treatment Urol Oncol 26 2008 57 64
24. G.J. Charrois, and T.M. Allen Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer Biochim Biophys Acta 1663 2004 167 177
25. L. Zhang, F.X. Gu, J.M. Chan, A.Z. Wang, R.S. Langer, and O.C. Farokhzad Nanoparticles in medicine: therapeutic applications and developments Clin Pharmacol Ther 83 2008 761 769
26. Clinical trials.gov A services of U.S National Institutes of Health. Available at: www.clinicaltrials.gov. Accessed September 14, 2015.
27. V.A. Johnson, E.K. Singh, L.A. Nazarova, L.D. Alexander, and S.R. McAlpine Macrocyclic inhibitors of hsp90 Curr Top Med Chem 10 2010 1380 1402
28. M.S. Goldberg, S.S. Hook, A.Z. Wang, and et al. Biotargeted nanomedicines for cancer: six tenets before you begin Nanomedicine (Lond) 8 2013 299 308
29. P. Moseley Stress proteins and the immune response Immunopharmacology 48 2000 299 302
30. D. Kültz Molecular and evolutionary basis of the cellular stress response Annu Rev Physiol 67 2005 225 257
31. E.T. Soo, G.W. Yip, Z.M. Lwin, S.D. Kumar, and B.H. Bay Heat shock proteins as novel therapeutic targets in cancer In vivo 22 2008 311 315
32. C.E.W. Steinberg Heat Shock Proteins: The Minimal, but Universal, Stress Proteome 2012 Springer Netherlands 107 130
33. Z. Li, and P. Srivastava Heat-shock proteins Current Protocols in Immunology/edited by John E Coligan [et al] Appendix 1 2004 Appendix 1T
34. M.D. Moltó, L. Pascual, and R. de Frutos Puff activity after heat shock in two species of the Drosophila obscura group Experientia 43 1987 1225 1227
35. R. Dutta, and M. Inouye GHKL, an emergent ATPase/kinase superfamily Trends Biochem Sci 25 2000 24 28
36. L.H. Pearl, and C. Prodromou Structure and in vivo function of Hsp90 Curr Opin Struct Biol 10 1 2000 46 51
37. C.E. Stebbins, A.A. Russo, C. Schneider, N. Rosen, F.U. Hartl, and N.P. Pavletich Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent Cell 89 1997 239 250
38. Hsp90 interactors. Available at: www.picard.ch/downloads. Accessed September 14, 2015.
39. A. Citri, D. Harari, G. Shohat, and et al. Hsp90 recognizes a common surface on client kinases J Biol Chem 281 2006 14361 14369
40. L. Neckers Hsp90 inhibitors as novel cancer chemotherapeutic agents Trends Mol Med 8 2002 S55 S61
41. L. Whitesell, and S.L. Lindquist HSP90 and the chaperoning of cancer Nat Rev Cancer 5 2005 761 772
42. L. Neckers Heat shock protein 90: the cancer chaperone J Biosci 32 2007 517 530
43. B. Becker, G. Multhoff, B. Farkas, and et al. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases Exp Dermatol 13 2004 27 32
44. S. Moriya, K. Yanagihara, H. Fujita, and N. Kuzumaki Differential expression of hsp90, gelsolin and gst-pi in human gastric-carcinoma cell-lines Int J Oncol 5 1994 1347 1351
45. Y. Yufu, J. Nishimura, and H. Nawata High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells Leuk Res 16 1992 597 605
46. G.P. Nagaraju, T.E. Long, W. Park, and et al. Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer Mol Carcinog 54 10 2015 1147 1158
47. D.B. Solit, and G. Chiosis Development and application of Hsp90 inhibitors Drug Discov Today 13 2008 38 43
48. E.G. Mimnaugh, W. Xu, M. Vos, and et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity Mol Cancer Ther 3 2004 551 566
49. K. Ueda, C. Cardarelli, M.M. Gottesman, and I. Pastan Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine Proc Natl Acad Sci U S A 84 1987 3004 3008
50. A.R. Kinsella, D. Smith, and M. Pickard Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage Br J cancer 75 1997 935 945
51. S.L. Rutherford, and S. Lindquist Hsp90 as a capacitor for morphological evolution Nature 396 1998 336 342
52. C. Queitsch, T.A. Sangster, and S. Lindquist Hsp90 as a capacitor of phenotypic variation Nature 417 2002 618 624
53. S.K. Calderwood, M.A. Khaleque, D.B. Sawyer, and D.R. Ciocca Heat shock proteins in cancer: chaperones of tumorigenesis Trends Biochem Sci 31 2006 164 172
54. L.M. Vargas-Roig, F.E. Gago, O. Tello, J.C. Aznar, and D.R. Ciocca Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy Int J Cancer 79 1998 468 475
55. S.B. Nadin, L.M. Vargas-Roig, F.D. Cuello-Carrión, and D.R. Ciocca Deoxyribonucleic acid damage induced by doxorubicin in peripheral blood mononuclear cells: possible roles for the stress response and the deoxyribonucleic acid repair process Cell Stress Chaperones 8 2003 361 372
56. K.S. Bisht, C.M. Bradbury, D. Mattson, and et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity Cancer Res 63 2003 8984 8995
57. T.E. Schmid, and G. Multhoff Radiation-induced stress proteins - the role of heat shock proteins (HSP) in anti- tumor responses Curr Med Chem 19 2012 1765 1770
58. S. He, D.L. Smith, M. Sequeira, J. Sang, R.C. Bates, and D.A. Proia The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer Invest New Drugs 32 4 2014 577 586
59. M.E. Murphy The HSP70 family and cancer Carcinogenesis 34 2013 1181 1188
60. P. Workman Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics Mol Cancer Ther 2 2003 131 138
61. R. Voellmy Transduction of the stress signal and mechanisms of transcriptional regulation of heat shock/stress protein gene expression in higher eukaryotes Crit Rev Eukaryot Gene Expr 4 1994 357 401
62. R.I. Morimoto Cells in stress: transcriptional activation of heat shock genes Science 259 1993 1409 1410
63. R.L. Juliano, and V. Ling A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim Biophys Acta 455 1976 152 162
64. J.R. Riordan, K. Deuchars, N. Kartner, N. Alon, J. Trent, and V. Ling Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines Nature 316 1985 817 819
65. M. Miyazaki, K. Kohno, T. Uchiumi, and et al. Activation of human multidrug resistance-1 gene promoter in response to heat shock stress Biochem Biophys Res Commun 187 1992 677 684
66. N.E. Vilaboa, A. Galán, A. Troyano, E. de Blas, and P. Aller Regulation of multidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1) J Biol Chem 275 2000 24970 24976
67. T. Tchénio, M. Havard, L.A. Martinez, and F. Dautry Heat shock-independent induction of multidrug resistance by heat shock factor 1 Mol Cell Biol 26 2006 580 591
68. K. Krishnamurthy, K. Vedam, R. Kanagasabai, L.J. Druhan, and G. Ilangovan Heat shock factor-1 knockout induces multidrug resistance gene, MDR1b, and enhances P-glycoprotein (ABCB1)-based drug extrusion in the heart Proc Natl Acad Sci U S A 109 2012 9023 9028
69. A.K. Rochani, M. Singh, and U. Tatu Heat shock protein 90 inhibitors as broad spectrum anti-infectives Curr Pharm Des 19 2013 377 386
70. A.K. Rochani, C. Mithra, M. Singh, and U. Tatu Heat shock protein 90 as a potential drug target against surra Parasitology 141 9 2014 1148 1155
71. G. Banumathy, V. Singh, S.R. Pavithra, and U. Tatu Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes J Biol Chem 278 2003 18336 18345
72. E. Dolgin, and A. Motluk Heat shock and awe Nat Med 17 2011 646 649
73. L.E. Cowen, and S. Lindquist Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi Science 309 2005 2185 2189
74. D.A. Guertin, and D.M. Sabatini Defining the role of mTOR in cancer Cancer Cell 12 1 2007 9 22
75. B.H. Jiang, and L.Z. Liu Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment Drug Resist Updat 11 2008 63 76
76. T. Guettouche, F. Boellmann, W.S. Lane, and R. Voellmy Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress BMC Biochem 6 2005 4
77. I. Shamovsky, and E. Nudler New insights into the mechanism of heat shock response activation Cell Mol Life Sci 65 2008 855 861
78. S.D. Chou, T. Prince, J. Gong, and S.K. Calderwood mTOR is essential for the proteotoxic stress response, HSF1 activation and heat shock protein synthesis PLoS One 7 2012 e39679
79. N. Terada, H.R. Patel, K. Takase, K. Kohno, A.C. Nairn, and E.W. Gelfand Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins Proc Natl Acad Sci U S A 91 1994 11477 11481
80. A.C. Gingras, S.P. Gygi, B. Raught, and et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism Genes Dev 13 1999 1422 1437
81. R.A. Randle, S. Raguz, C.F. Higgins, and E. Yagüe Role of the highly structured 5'-end region of MDR1 mRNA in P-glycoprotein expression Biochem J 406 2007 445 455
82. A.K. McCollum, C.J. TenEyck, B. Stensgard, and et al. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response Cancer Res 68 2008 7419 7427
83. H. Liu, H. Sun, Z. Wu, X. Zhang, and B. Wu P-glycoprotein (P-gp)-mediated efflux limits intestinal absorption of the Hsp90 inhibitor SNX-2112 in rats Xenobiotica 44 2014 763 768
84. L. Whitesell, E.G. Mimnaugh, B. De Costa, C.E. Myers, and L.M. Neckers Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation Proc Natl Acad Sci U S A 91 1994 8324 8328
85. Y. Uehara, Y. Murakami, S. Mizuno, and S. Kawai Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A Virology 164 1988 294 298
86. L. Whitesell, S.D. Shifrin, G. Schwab, and L.M. Neckers Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition Cancer Res 52 1992 1721 1728
87. C. DeBoer, P.A. Meulman, R.J. Wnuk, and D.H. Peterson Geldanamycin, a new antibiotic J Antibiot 23 1970 442 447
88. S. Omura, Y. Iwai, Y. Takahashi, and et al. Herbimycin, a new antibiotic produced by a strain of Streptomyces J Antibiot 32 1979 255 261
89. W. Lang, G.W. Caldwell, J. Li, G.C. Leo, W.J. Jones, and J.A. Masucci Biotransformation of geldanamycin and 17-allylamino-17-demethoxygeldanamycin by human liver microsomes: reductive versus oxidative metabolism and implications Drug Metab Dispos 35 2007 21 29
90. T.W. Schulte, and L.M. Neckers The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin Cancer Chemother Pharmacol 42 1998 273 279
91. A.J. Wagner, R. Chugh, L.S. Rosen, and et al. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas Clin Cancer Res 19 2013 6020 6029
92. H. He, D. Zatorska, J. Kim, and et al. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90 J Med Chem 49 2006 381 390
93. L. Llauger, H. He, J. Kim, and et al. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90 J Med Chem 48 2005 2892 2905
94. P.A. Brough, W. Aherne, X. Barril, and et al. 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer J Med Chem 51 2008 196 218
95. S.A. Eccles, A. Massey, F.I. Raynaud, and et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis Cancer Res 68 2008 2850 2860
96. Y. Okawa, T. Hideshima, P. Steed, and et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK Blood 113 2009 846 855
97. S. Chandarlapaty, A. Sawai, Q. Ye, and et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers Clin Cancer Res 14 2008 240 248
98. K.H. Huang, J.M. Veal, R.P. Fadden, and et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents J Med Chem 52 2009 4288 4305
99. S. Soga, S. Akinaga, and Y. Shiotsu Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development Curr Pharm Des 19 3 2013 366 376
100. U. Banerji, A. O'Donnell, M. Scurr, and et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies J Clin Oncol 23 2005 4152 4161
101. H.A. Burris, D. Berman, B. Murthy, and S. Jones Tanespimycin pharmacokinetics: A randomized dose-escalation crossover phase 1 study of two formulations Cancer Chemother Pharmacol 67 2011 1045 1054
102. L. Neckers, and P. Workman Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18 1 2012 64 76
103. Bristol-Myers Squibb Halts Development of Tanespimycin. Available at: http://www.myelomabeacon.com/news/2010/07/22/tanespimycin-development-halted/. Accessed September 14, 2015.
104. Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib. Available at: https://clinicialtrials.gov/ct2/results?term=NCT00688766&Search=Search. Accessed September 14, 2015.
105. S. Modi, C. Saura, C. Henderson, and et al. A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer Breast Cancer Res Treat 139 2013 107 113
106. Infinity Reports Topline Data from Phase 2 Study of Retaspimycin Hydrochloride, Its Hsp90 Inhibitor, in Patients with Non-Small Cell Lung Cancer. Available at: http://www.businesswire.com/news/home/20130925005707/en/Infinity-Reports-Topline-Data-Phase-2-Study#.VZND1Ruqqko. Accessed September 14, 2015.
107. S. Pacey, R.H. Wilson, M. Walton, and et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors Clin Cancer Res 17 2011 1561 1570
108. K. Jhaveri, T. Taldone, S. Modi, and G. Chiosis Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers Biochim Biophys Acta 1823 2012 742 755
109. K. Jhaveri, K. Miller, L. Rosen, and et al. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors Clin Cancer Res 18 2012 5090 5098
110. J. Choi, J. Chen, S.L. Schreiber, and J. Clardy Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP Science 273 5272 1996 239 242
111. L.K. Francis, Y. Alsayed, X. Leleu, and et al. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma Clin Cancer Res 12 2006 6826 6835
112. D.P. Mansi Parasramka, E. Dan Serie, A. Thompson, and R.W. Joseph Preclinical Activity of the Heat Shock Protein 90 (Hsp90) Inhibitor Ganetespib in Clear Cell Renal Cell (ccRCC) 2014 Synta Pharmaceutical Lexington, MA
113. M.M. Martina Schwarzkopf, and M.P. Gray Curis and Debiopharm Group™ Announce Initiation of Phase I Dose Finding Clinical Study With a Combination of HSP90 Inhibitor Debio 0932 and Everolimus 2013 Curis and Debiopharm Lausanne, Switzerland
114. M. Uner, and G. Yener Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives Int J Nanomedicine 2 2007 289 300
115. J. Madan, R.S. Pandey, V. Jain, O.P. Katare, R. Chandra, and A. Katyal Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells Nanomedicine 9 2013 492 503
116. S. Karve, M.E. Werner, R. Sukumar, and et al. Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery Proc Natl Acad Sci U S A 109 2012 8230 8235
117. K. Greish Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting Methods Mol Biol 624 2010 25 37
118. W.B. Liechty, D.R. Kryscio, B.V. Slaughter, and N.A. Peppas Polymers for drug delivery systems Annu Rev Chem Biomol Eng 1 2010 149 173
119. H.K. Sajja, M.P. East, H. Mao, Y.A. Wang, S. Nie, and L. Yang Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect Curr Drug Discov Technol 6 2009 43 51
120. A.D. Bangham, R.W. Horne, A.M. Glauert, J.T. Dingle, and J.A. Lucy Action of saponin on biological cell membranes Nature 196 1962 952 955
121. R.W. Horne, A.D. Bangham, and V.P. Whittaker Negatively stained lipoprotein membranes Nature 200 1963 1340
122. G. Sessa, and G. Weissmann Phospholipid spherules (liposomes) as a model for biological membranes J Lipid Res 9 1968 310 318
123. G. Gregoriadis, and B.E. Ryman Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases Biochem J 124 1971 58P
124. G. Gregoriadis, P.D. Leathwood, and B.E. Ryman Enzyme entrapment in liposomes FEBS Lett 14 1971 95 99
125. G. Gregoriadis, E.J. Wills, C.P. Swain, and A.S. Tavill Drug-carrier potential of liposomes in cancer chemotherapy Lancet 1 1974 1313 1316
126. Y.E. Rahman, E.A. Cerny, S.L. Tollaksen, B.J. Wright, S.L. Nance, and J.F. Thomson Liposome-encapsulated actinomycin D: potential in cancer chemotherapy Proc Soc Exp Biol Med 146 1974 1173 1176
127. C.M. Colley, and B.E. Ryman Liposomes as carriers in vivo for methotrexate Biochem Soc Trans 3 1975 157 159
128. N.O. Dhoot, and M.A. Wheatley Microencapsulated liposomes in controlled drug delivery: strategies to modulate drug release and eliminate the burst effect J Pharm Sci 92 2003 679 689
129. C. Dong, and J.A. Rogers Quantitative determination of carboxymethyl chitin in polymer-coated liposomes J Microencapsul 8 1991 153 160
130. D.W. Northfelt, B.J. Dezube, J.A. Thommes, and et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial J Clin Oncol 16 1998 2445 2451
131. K. Sen, and M. Mandal Second generation liposomal cancer therapeutics: transition from laboratory to clinic Int J Pharm 448 2013 28 43
132. C. Mamot, R. Ritschard, A. Wicki, and et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study Lancet Oncol 13 2012 1234 1241
133. Y. Matsumura, M. Gotoh, K. Muro, and et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer Ann Oncol 15 2004 517 525
134. A. Mukherjee, K.P. Narayan, K. Pal, and et al. Selective cancer targeting via aberrant behavior of cancer cell-associated glucocorticoid receptor Mol Ther 17 2009 623 631
135. S.K. Pore, A. Choudhary, B. Rathore, and et al. Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect Biomaterials 34 2013 6804 6817
136. W. Dai, F. Yang, L. Ma, and et al. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer Biomaterials 35 2014 5347 5358
137. M.A. Rouf, I. Vural, J.M. Renoir, and A.A. Hincal Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells J Liposome Res 19 2009 322 331
138. M. Umrethia, P.K. Ghosh, R. Majithya, and R.S.R. Murthy 6-mercaptopurine (6-MP) entrapped stealth liposomes for improvement of leukemic treatment without hepatotoxicity and nephrotoxicity Cancer Invest 25 2007 117 123
139. J. Guo, X. Gao, L. Su, and et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery Biomaterials 32 2011 8010 8020
140. J.W. Park, K. Hong, D.B. Kirpotin, and et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery Clin Cancer Res 8 2002 1172 1181
141. A. Aravind, R. Nair, S. Raveendran, and et al. Aptamer conjugated paclitaxel and magnetic fluid loaded fluorescently tagged PLGA nanoparticles for targeted cancer therapy J Magn Magn Mater 344 2013 116 123
142. H.M. Mansour, M. Sohn, A. Al-Ghananeem, and P.P. Deluca Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects Int J Mol Sci 11 2010 3298 3322
143. D. Mallardé, F. Boutignon, F. Moine, and et al. PLGA-PEG microspheres of teverelix: influence of polymer type on microsphere characteristics and on teverelix in vitro release Int J Pharm 261 2003 69 80
144. G. Ruan, and S.-S. Feng Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel Biomaterials 24 2003 5037 5044
145. H.K. Makadia, and S.J. Siegel Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier Polymers (Basel) 3 2011 1377 1397
146. B. Zhao, X.Q. Wang, X.Y. Wang, and et al. Nanotoxicity comparison of four amphiphilic polymeric micelles with similar hydrophilic or hydrophobic structure Part Fibre Toxicol 10 2013 47
147. M. Gou, X. Wei, K. Men, and et al. PCL/PEG copolymeric nanoparticles: potential nanoplatforms for anticancer agent delivery Curr Drug Targets 12 2011 1131 1150
148. A. Fernández-Carballido, P. Pastoriza, E. Barcia, C. Montejo, and S. Negro PLGA/PEG-derivative polymeric matrix for drug delivery system applications: characterization and cell viability studies Int J Pharm 352 2008 50 57
149. R. Tong, N.P. Gabrielson, T.M. Fan, and J. Cheng Polymeric nanomedicines based on poly(lactide) and poly(lactide-co-glycolide) Curr Opin Solid State Mater Sci 16 6 2012 323 332
150. J.M. Chan, P.M. Valencia, L. Zhang, R. Langer, and O.C. Farokhzad Polymeric nanoparticles for drug delivery Methods Mol Biol 624 2010 163 175
151. Johnson RG, Hannah AL, Cropp GF, Zhou Y, Sherrill JM. Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either. US patent 7691392 B2. 2010.
152. M.P. Xiong, J.A. Yáñez, G.S. Kwon, N.M. Davies, and M.L. Forrest A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats J Pharm sci 98 2009 1577 1586
153. T. Chandran, U. Katragadda, Q. Teng, and C. Tan Design and evaluation of micellar nanocarriers for 17-allyamino-17-demethoxygeldanamycin (17-AAG) Int J Pharm 392 2010 170 177
154. V. Saxena, Y. Naguib, and M.D. Hussain Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer Colloids Surf B Biointerfaces 94 2012 274 280
155. Z. Wei, S. Yuan, J. Hao, and X. Fang Mechanism of inhibition of P-glycoprotein mediated efflux by Pluronic P123/F127 block copolymers: relationship between copolymer concentration and inhibitory activity Eur J Pharm Biopharm 83 2 2013 266 274
156. V. Saxena, and M.D. Hussain Formulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma multiforme Colloids Surf B Biointerfaces 112 2013 350 355
157. R. Pradhan, B.K. Poudel, J.Y. Choi, and et al. Preparation and evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG)-loaded poly(lactic acid-co-glycolic acid) nanoparticles Arch Pharm Res 38 5 2015 734 741
158. M.S. Kim, J.S. Kim, H.J. Park, W.K. Cho, K.H. Cha, and S.J. Hwang Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process Int J Nanomedicine 6 2011 2997 3009
159. S. Moeller, R. Kegler, K. Sternberg, and R.G. Mundkowski Influence of sirolimus-loaded nanoparticles on physiological functions of native human polymorphonuclear neutrophils Nanomedicine 8 2012 1293 1300
160. Z. Zhang, L. Xu, H. Chen, and X. Li Rapamycin-loaded poly(ϵ-caprolactone)-poly(ethylene glycol)-poly(ϵ-caprolactone) nanoparticles: preparation, characterization and potential application in corneal transplantation J Pharm Pharmacol 66 2014 557 563
161. X. Shi, G. Chen, L.W. Guo, and et al. Periadventitial application of rapamycin-loaded nanoparticles produces sustained inhibition of vascular restenosis PLoS One 9 2014 e89227
162. W. Zou, G. Cao, Y. Xi, and N. Zhang New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles Drug Deliv 16 2009 15 23
163. H.C. Shin, A.W. Alani, H. Cho, Y. Bae, J.M. Kolesar, and G.S. Kwon A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs Mol Pharm 8 2011 1257 1265
164. J.R. Hasenstein, H.C. Shin, K. Kasmerchak, D. Buehler, G.S. Kwon, and K.R. Kozak Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG Mol Cancer Ther 11 2012 2233 2242
165. H.C. Shin, H. Cho, T.C. Lai, K.R. Kozak, J.M. Kolesar, and G.S. Kwon Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin J Control Release 163 2012 93 99
166. J.J. Barrott, and T.A. Haystead Hsp90, an unlikely ally in the war on cancer FEBS J 280 6 2013 1381 1396
167. J. Brugarolas, K. Lei, R.L. Hurley, and et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex Genes Dev 18 23 2004 2893 2904
168. S. Katiyar, E. Liu, C.A. Knutzen, and et al. REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase EMBO Rep 10 8 2009 866 872
169. D.D. Von Hoff There are no bad anticancer agents, only bad clinical trial designs-twenty-first Richard and Hinda Rosenthal Foundation Award Lecture Clin Cancer Res 4 1998 1079 1086
170. A. Jimeno, M.A. Rudek, P. Kulesza, and et al. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors J Clin Oncol 26 2008 4172 4179
171. K. Hu, S. Cao, F. Hu, and J. Feng Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation Int J Nanomedicine 7 2012 3537 3545
172. M. Al-Hajeili, A.S. Azmi, and M. Choi Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer Onco Targets Ther 7 2014 187 192
173. I. Cucinotto, L. Fiorillo, S. Gualtieri, and et al. Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J Drug Deliv 2013 2013 905091
174. E. Miele, G.P. Spinelli, E. Miele, F. Tomao, and S. Tomao Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer Int J Nanomedicine 4 2009 99 105
175. C Tao, C Yu, TK De, and et al. Preparation of nanoparticle albumin bound 17AAG (nab-17AAG) suitable for intravenous administration Proc Amer Assoc Cancer Res 46 2005
176. Y.W. Won, S.M. Yoon, C.H. Sonn, K.M. Lee, and Y.H. Kim Nano self-assembly of recombinant human gelatin conjugated with alpha-tocopheryl succinate for Hsp90 inhibitor, 17-AAG, delivery ACS Nano 5 5 2005 3839 3848
177. A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies. Available at: https://clinicaltrials.gov/ct2/results?term=NCT00820768&Search=Search. Accessed September 14, 2015.
178. Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer. Available at: https://clinicaltrials.gov/ct2/results?term=NCT02009332&Search=Search. Accessed September 14, 2015.
179. S. Modi, A.T. Stopeck, M.S. Gordon, and et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study J Clin Oncol 25 2007 5410 5417
180. V. Wagner, B. Husing, and S. Gaisser Nanomedicine: Drivers for Development and Possible Impacts 2008 European Commission Joint Research Centre Institute for Prospective Technological Studies Düsseldorf, Germany
181. Nanotechnology in Medical Applications: The Global Market. Available at: http://www.bccresearch.com/market-research/healthcare/nanotechnology-medical-applications-hlc069a.html. Accessed September 14, 2015.
182. V. Morigi, A. Tocchio, C. Bellavite Pellegrini, J.H. Sakamoto, M. Arnone, and E. Tasciotti Nanotechnology in medicine: from inception to market domination J Drug Deliv 2012 2012 389485
183. Market opportunities. Available at: http://www.etp-nanomedicine.eu/public/about-nanomedicine/market-opportunities. Accessed September 14, 2015.